<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8809320</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1600</journal-id>
<journal-id journal-id-type="nlm-ta">Neuron</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuron</journal-id>
<journal-title-group>
<journal-title>Neuron</journal-title>
</journal-title-group>
<issn pub-type="ppub">0896-6273</issn>
<issn pub-type="epub">1097-4199</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30844401</article-id>
<article-id pub-id-type="pmc">6407643</article-id>
<article-id pub-id-type="doi">10.1016/j.neuron.2019.01.056</article-id>
<article-id pub-id-type="manuscript">NIHMS1522064</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Belloy</surname>
<given-names>Michaël E.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Napolioni</surname>
<given-names>Valerio</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Greicius</surname>
<given-names>Michael D.</given-names>
</name>
</contrib>
<aff id="A1">Department of Neurology and Neurological Sciences, FIND Lab, Stanford University, Stanford, CA, 94304, USA</aff>
</contrib-group>
<author-notes>
<corresp id="CR1"><label>*</label>Correspondence: <email>greicius@stanford.edu</email></corresp>
<fn fn-type="COI-statement" id="FN3">
<p id="P38">Declaration of interest</p>
<p id="P39">The authors declare no competing interests.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<day>06</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>06</day>
<month>3</month>
<year>2020</year>
</pub-date>
<volume>101</volume>
<issue>5</issue>
<fpage>820</fpage>
<lpage>838</lpage>
<!--elocation-id from pubmed: 10.1016/j.neuron.2019.01.056-->
<abstract id="ABS1">
<p id="P2">Alzheimer’s disease (AD) is considered a polygenic disorder. This view is clouded, however, by lingering uncertainty over how to treat the quasi “monogenic” role of apolipoprotein E (<italic>APOE</italic>). The <italic>APOE</italic>4 allele is not only the strongest genetic risk factor for AD, it also affects risk for cardiovascular disease, stroke, and other neurodegenerative disorders. This review, based mostly on data from human studies, ranges across a variety of <italic>APOE</italic>-related pathologies, touching on evolutionary genetics and risk mitigation by ethnicity and sex. The authors also address one of the most fundamental question pertaining to <italic>APOE</italic>4 and AD: Does APOE4 increase AD risk via a loss- or gain-of-function? The answer will be of the utmost importance in guiding future research in AD.</p>
</abstract>
<abstract abstract-type="Summary" id="ABS2">
<title>In brief</title>
<p id="P3">Does <italic>APOE</italic>4 increase risk for Alzheimer’s disease via a gain- or loss-of-function? Belloy, et al., focusing on human data, examine critical issues like pleiotropy, sex, and ancestral background, to address this fundamental question.</p>
</abstract>
<kwd-group>
<kwd>Apolipoprotein E (APOE)</kwd>
<kwd>Alzheimer’s disease (AD)</kwd>
<kwd>neurodegenerative disease</kwd>
<kwd>cardiovascular disease</kwd>
<kwd>pleiotropy</kwd>
<kwd>evolutionary genetics</kwd>
<kwd>ethnicity</kwd>
<kwd>sex</kwd>
<kwd>gene-based therapy</kwd>
<kwd>anti-sense oligonucleotide (ASO)</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>